0000000000455436

AUTHOR

Greco F.

showing 3 related works from this author

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a m…

2023

BackgroundIn triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based on the results of the randomized CREATE-X study, carried out in Asian patients and including a small subset of triple negative tumors. Thus far, evidence on Caucasian patients is limited, and no real-world data are available.MethodsWe carried out a multicenter, observational study, involving 44 oncologic centres. Triple negative breast cancer patients with residual disease, treated with adjuvant capecitabine from January 2017 through June 2021, were recrui…

neoadjuvant treatmentCancer ResearchOncologytriple negative breast canceradjuvant capecitabineresidual tumorsresidual tumortreatment discontinuationFrontiers in Oncology
researchProduct

Has VZV epidemiology changed in Italy? Results of a seroprevalence study

2017

The aim of the study was to evaluate if and how varicella prevalence has changed in Italy. In particular a seroprevalence study was performed, comparing it to similar surveys conducted in pre-immunization era. During 2013–2014, sera obtained from blood samples taken for diagnostic purposes or routine investigations were collected in collaboration with at least one laboratory/center for each region, following the approval of the Ethics Committee. Data were stratified by sex and age. All samples were processed in a national reference laboratory by an immunoassay with high sensitivity and specificity. Statutory notifications, national hospital discharge database and mortality data related to V…

Male0301 basic medicinePediatricsCross-sectional studySeroprevalenceSettore MED/42 - Igiene Generale E ApplicataAntibodies Viralmedicine.disease_causeChickenpox0302 clinical medicineChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster Virus; Adolescent; Adult; Age Factors; Aged; Aged 80 and over; Antibodies Viral; Chickenpox; Child; Child Preschool; Cross-Sectional Studies; Female; Humans; Infant; Infant Newborn; Italy; Male; Middle Aged; Seroepidemiologic Studies; Young Adult; Immunology and Allergy; Immunology; PharmacologySeroepidemiologic StudiesEpidemiology80 and overImmunology and AllergyAge FactorViral030212 general & internal medicineYoung adultChildskin and connective tissue diseasesAged 80 and overSurveillanceChickenpoxVaricella-Zoster ViruAge FactorsMiddle AgedResearch PapersItalyChild PreschoolFemaleChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster Virus; Immunology and Allergy; Immunology; PharmacologyHumanAdultmedicine.medical_specialtyAdolescent030106 microbiologyImmunologyAntibodiesNOYoung Adult03 medical and health sciencesChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster VirusmedicineHumansSeroprevalencePreschoolAgedCross-Sectional StudiePharmacologybusiness.industrySeroepidemiologic StudieInfant NewbornVaricella zoster virusInfantSeroepidemiologic StudiesNewbornmedicine.diseaseVaricella-Zoster VirusCross-Sectional StudiesImmunizationImmunizationsense organsChickenpox Immunization Seroprevalence Surveillance Varicella-Zoster Virus Immunology and Allergy Immunology Pharmacologybusiness
researchProduct

Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021

2021

COVID study groups - PORTUGAL: Portuguese Laboratory Network for the Diagnosis of COVID-19 and Public Health Department of the Health Administrative Regions, Physicians that provided data and samples from suspected cases and SARS-CoV-2 genetic characterization. INSA laboratory team for the diagnosis of SARS-CoV-2. Algarve Biomedical Center and Unilabs. We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95…

Infecções Respiratórias2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Critical CareEpidemiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)variants of concernSettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineVirologyInternal medicineMedicineHumansIntensive care admission030212 general & internal medicineCOVID-19; Europe; SARS-CoV-2; surveillance; variants of concern; Critical Care; Europe; Humans; COVID-19; SARS-CoV-2Surveillancebusiness.industrySARS-CoV-2030503 health policy & servicesPublic Health Environmental and Occupational HealthCOVID-19Odds ratioConfidence intervalEuropesurveillanceVariants of ConcernCOVID-19 Europe SARS-CoV-2 surveillance variants of concern0305 other medical sciencebusinessRapid CommunicationHuman
researchProduct